# Polydatin (Polygonum cuspidatum)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/polydatin-polygonum-cuspidatum
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** Piceid, Resveratrol-3-O-β-D-glucoside, 3,4′,5-trihydroxystilbene-3-β-D-glucoside, trans-Polydatin, CAS 65914-17-2

## Overview

Polydatin (resveratrol-3-O-β-D-glucoside) is a glycosylated stilbenoid that exerts [antioxidant](/ingredients/condition/antioxidant) and [anti-inflammatory](/ingredients/condition/inflammation) effects by activating the Nrf2/HO-1 axis, inhibiting NF-κB/TLR4 signaling, promoting autophagic flux, and suppressing ROS/RNS generation across multiple organ systems. Preclinical evidence across cell lines and rodent models demonstrates organ-protective, anticancer, and [neuroprotective](/ingredients/condition/cognitive) activities, though no standardized human clinical dosing or phase II/III trial data have been published as of 2024.

## Health Benefits

- **Antioxidant Defense**: Polydatin activates the Keap1/Nrf2 pathway—partly via upregulation of miR-200a—to induce heme oxygenase-1 (HO-1) and other cytoprotective enzymes, significantly reducing intracellular ROS and RNS in models of LPS-induced neuroinflammation and ischemia-reperfusion injury.
- **Anti-Inflammatory Activity**: By suppressing TLR4/NF-κB p65 signaling, polydatin reduces transcription of [pro-inflammatory cytokine](/ingredients/condition/inflammation)s (TNF-α, IL-1β, IL-6) and limits macrophage recruitment and hepatic stellate cell activation in liver disease models.
- **Neuroprotection**: In rodent spinal cord injury (SCI) models, polydatin administration improved locomotor performance scores and reduced spinal cord edema, with mechanistic attribution to Nrf2/HO-1 activation and attenuation of [lipid peroxidation](/ingredients/condition/antioxidant).
- **[Hepatoprotect](/ingredients/condition/detox)ion and Anti-Fibrosis**: Polydatin inhibits ER stress-linked [autophagy](/ingredients/condition/longevity) and TLR4/NF-κB-driven fibrogenic signaling, reducing collagen deposition and hepatic stellate cell activation in non-alcoholic fatty liver and fibrosis animal models.
- **Anticancer Properties**: In hepatocellular carcinoma (HCC), colorectal, and lung cancer models, polydatin blocks PI3K/AKT and Wnt/β-catenin pathways, upregulates pro-apoptotic Bax and caspases-3/9, downregulates Bcl-2 and STAT3, and induces G6PD inhibition to impair the pentose phosphate pathway supporting tumor [metabolism](/ingredients/condition/weight-management).
- **Cardioprotection**: Polydatin attenuates doxorubicin- and cisplatin-induced cardiotoxicity and nephrotoxicity in rodent models through its antioxidant mechanisms, suggesting a potential adjunct role in reducing chemotherapy-related organ damage.
- **Osteogenic Promotion**: Preliminary cell-based studies indicate polydatin stimulates osteogenic differentiation of mesenchymal stem cells (MSCs), offering a mechanistic rationale for exploration in [osteoporosis](/ingredients/condition/bone-health) and bone repair contexts.

## Mechanism of Action

Polydatin's primary [antioxidant](/ingredients/condition/antioxidant) mechanism involves upregulating miR-200a to suppress Keap1, thereby freeing Nrf2 to translocate to the nucleus and transcribe HO-1, NQO1, and [glutathione](/ingredients/condition/detox)-synthesizing enzymes, collectively reducing oxidative burden. Simultaneously, it inhibits the TLR4/MyD88/[NF-κB](/ingredients/condition/inflammation) p65 signaling cascade, preventing IκB phosphorylation and nuclear translocation of NF-κB, which diminishes transcription of TNF-α, IL-1β, and IL-6. In oncological contexts, polydatin disrupts PI3K/AKT, Wnt/β-catenin, and PDGF/Akt proliferative pathways, induces cytochrome c release from mitochondria to activate caspase-9 and caspase-3, and inhibits glucose-6-phosphate dehydrogenase (G6PD) to impair NADPH production and biosynthetic flux in cancer cells. The intact glucoside structure confers improved aqueous solubility and intestinal absorption compared to aglycone resveratrol, with β-glucosidase activity in the gut and liver contributing to partial conversion to free resveratrol, enabling a dual-molecule pharmacological profile.

## Clinical Summary

No human randomized controlled trials with reported sample sizes, primary endpoints, or effect sizes have been completed and published for polydatin as an isolated supplement. The entire clinical-inference framework relies on extrapolation from rodent efficacy models—including SCI models, NASH/fibrosis models, and cancer xenograft models—where effect sizes are substantial but species-specific [metabolism](/ingredients/condition/weight-management) limits direct translation. Researchers have proposed polydatin as an adjunct to tyrosine kinase inhibitors (TKIs) and doxorubicin based on in vitro synergy data, but no combination clinical trials exist. Confidence in human clinical outcomes must therefore be rated as low pending adequately powered phase II trials with pharmacokinetic endpoints and standardized extract dosing.

## Nutritional Profile

Polydatin is a pure stilbenoid polyphenol (molecular weight 390.38 g/mol; CAS 65914-17-2) and does not contribute macronutrients, vitamins, or minerals in supplemental doses. As a resveratrol glucoside (3,4′,5-trihydroxystilbene-3-β-D-glucoside), it contains one glucose moiety that is cleaved post-absorption, yielding free resveratrol and glucose in trace amounts—nutritionally insignificant. The primary phytochemical value lies in the intact polydatin molecule and its metabolites: free resveratrol (post-hydrolysis), resveratrol sulfates, and resveratrol glucuronides generated by hepatic phase II conjugation. Bioavailability relative to resveratrol is considered superior due to the glucose transporter (SGLT1/GLUT2)-facilitated intestinal uptake of the intact glucoside and improved aqueous solubility, though quantitative human bioavailability percentages are not yet established from published pharmacokinetic trials.

## Dosage & Preparation

- **Standardized Root Extract (P. cuspidatum)**: Typically standardized to 8–50% polydatin by HPLC; most commercial products supply 40–200 mg polydatin per serving, though no evidence-based human dose has been established.
- **Purified Polydatin Powder**: Used in research at concentrations of 10–100 μM in cell studies and 20–100 mg/kg/day in rodent studies; human-equivalent dose extrapolations using FDA body surface area scaling suggest rough ranges of 100–500 mg/day for a 70 kg adult, but this remains speculative without clinical validation.
- **Traditional Decoction (Hu Zhang)**: Dried P. cuspidatum root (9–15 g) boiled in water for 20–30 minutes per TCM pharmacopoeia; polydatin content in decoctions is variable and unquantified.
- **Ethanol Extract**: Used in research preparations; 70% ethanol is commonly used to maximize stilbenoid yield from dried root material during standardized manufacturing.
- **Timing**: No timing data from human trials; preclinical protocols administer daily oral doses, suggesting once or twice daily supplementation with meals to optimize absorption via intestinal lactase-phlorizin hydrolase activity.
- **Micelle/Nanoparticle Formulations (Experimental)**: Polydatin-loaded micellar complexes (PD-MC) have been explored for targeted hepatic delivery in animal liver disease models but are not commercially available.

## Safety & Drug Interactions

Polydatin has not been evaluated in formal human safety or toxicology trials, and no established tolerable upper intake level, NOAEL in humans, or maximum safe supplemental dose has been defined; preclinical rodent studies report no overt toxicity at research doses (up to 100 mg/kg/day), and the compound demonstrates a protective rather than exacerbating profile against cisplatin nephrotoxicity and doxorubicin cardiotoxicity in animal models. Theoretically, polydatin's inhibition of G6PD may be relevant for individuals with G6PD deficiency or those relying on [glycolysis](/ingredients/condition/weight-management)-dependent metabolic states, and its [antioxidant activity](/ingredients/condition/antioxidant) could theoretically interfere with pro-oxidant mechanisms of certain chemotherapy agents, warranting caution in oncology settings without clinician oversight. As a stilbenoid with structural similarity to resveratrol, potential interactions with CYP3A4, CYP2C9, and P-glycoprotein substrates are mechanistically plausible but unquantified in humans; caution is advised with anticoagulants (warfarin), antiplatelet drugs, and immunosuppressants. Pregnancy and lactation safety data are absent, and avoidance during these periods is prudent given the lack of human safety data; individuals with estrogen-sensitive conditions should consult a clinician given the phytoestrogenic activity reported for related stilbenoids.

## Scientific Research

The evidence base for polydatin is composed almost entirely of in vitro cell culture experiments and in vivo rodent or murine studies, with no published phase I, II, or III human clinical trials identified as of 2024, placing it firmly in the preclinical category. Animal studies have demonstrated statistically significant improvements in spinal cord injury locomotor scores (Basso-Beattie-Bresnahan scale), reductions in hepatic fibrosis markers (hydroxyproline, α-SMA), and tumor volume suppression in HCC xenograft models, though these results carry inherent translational limitations. Systematic and narrative reviews (e.g., published in Frontiers in Pharmacology, Phytomedicine, and Biomedicine & Pharmacotherapy) have synthesized this preclinical body of work, confirming mechanistic consistency across studies, but explicitly calling for pharmacokinetic characterization and randomized controlled trials in humans. The glycoside bioavailability advantage over resveratrol is supported by comparative pharmacokinetic studies in animals and limited ex vivo human tissue models, but human AUC and Cmax data with standardized doses remain unpublished.

## Historical & Cultural Context

Polygonum cuspidatum (Hu Zhang, 虎杖) has been documented in Traditional Chinese Medicine for over 2,000 years, referenced in texts including the Shennong Bencao Jing and later the Compendium of Materia Medica (Bencao Gangmu, 1596 CE), where it was prescribed as a bitter, cold herb to clear heat, resolve dampness, reduce jaundice, dispel blood stasis, and alleviate pain from rheumatism and traumatic injury. Preparations included water decoctions of the dried root and rhizome, topical poultices for burns and skin infections, and wine-based macerations for musculoskeletal complaints. The specific identification and isolation of polydatin as a discrete chemical entity dates to the latter half of the 20th century, with its structural characterization as a resveratrol glucoside reported in the pharmacognostic literature after improved chromatographic techniques became available in the 1970s–1980s. Japanese Kampo medicine similarly employed the equivalent herb (Ko-jo, イタドリ), and the young shoots remain a consumed vegetable in rural Japan, providing incidental dietary exposure to polydatin.

## Synergistic Combinations

Polydatin demonstrates preclinical synergy with tyrosine kinase inhibitors (TKIs) such as gefitinib and imatinib in cancer cell line models, where its suppression of PI3K/AKT and STAT3 pathways counteracts acquired TKI resistance mechanisms, producing additive to synergistic antiproliferative effects. In [oxidative stress](/ingredients/condition/antioxidant) contexts, co-administration with N-acetylcysteine (NAC) or alpha-lipoic acid is mechanistically complementary—polydatin drives transcriptional Nrf2 induction while NAC and lipoic acid replenish [glutathione](/ingredients/condition/detox) substrate pools, collectively amplifying antioxidant capacity across both inducible and constitutive defense arms. Combination with 2-deoxyglucose (2-DG), a [glycolysis](/ingredients/condition/weight-management) inhibitor, has shown enhanced cancer cell death in vitro by pairing polydatin's G6PD inhibition with 2-DG's hexokinase blockade, creating dual metabolic stress in tumor cells.

## Frequently Asked Questions

### What is the difference between polydatin and resveratrol?

Polydatin is the glycosylated form of resveratrol, with a glucose molecule attached at the 3-position of the stilbene backbone (resveratrol-3-O-β-D-glucoside), whereas resveratrol is the free aglycone. This glycosidic bond confers improved aqueous solubility and facilitates intestinal absorption via glucose transporters (SGLT1/GLUT2), making polydatin more bioavailable than free resveratrol; intestinal and hepatic β-glucosidases subsequently cleave the glucose to release resveratrol as a metabolite, meaning both molecules contribute to downstream pharmacological activity.

### Is polydatin safe to take as a supplement?

Human safety data for polydatin as an isolated supplement are essentially absent, as no published phase I clinical trials or formal toxicology studies in humans have been completed. Preclinical rodent studies at doses up to 100 mg/kg/day report no overt toxicity, and the compound appears to reduce rather than exacerbate organ damage from chemotherapy drugs in animal models. Until human pharmacokinetic and safety trials are conducted, supplementation should be approached cautiously, particularly by pregnant or breastfeeding individuals, those with G6PD deficiency, and anyone on anticoagulant, antiplatelet, or chemotherapy regimens.

### What is polydatin used for in traditional Chinese medicine?

In Traditional Chinese Medicine, polydatin's source plant Polygonum cuspidatum (Hu Zhang, 虎杖) has been used for over 2,000 years as a bitter, cold herb to clear heat and dampness, resolve jaundice, dispel blood stasis, reduce pain from rheumatism, and treat burns and skin infections. Preparations traditionally consisted of water decoctions of the dried root and rhizome (9–15 g per dose) or wine-based macerations; the specific isolation of polydatin as the active molecule is a modern pharmacognostic achievement and was not recognized in classical texts.

### What dose of polydatin should I take?

No evidence-based human supplemental dose for polydatin has been established, as clinical trials with dose-finding endpoints have not been published. Commercial standardized P. cuspidatum extracts typically deliver 40–200 mg of polydatin per serving, and rough human-equivalent dose extrapolations from rodent data (using FDA body surface area scaling) suggest a range of approximately 100–500 mg/day for a 70 kg adult, though this is speculative. Until pharmacokinetic studies define optimal exposure targets, following label directions on standardized extracts and consulting a qualified healthcare provider is the most prudent approach.

### Does polydatin have anti-cancer properties?

Preclinical in vitro and animal studies indicate that polydatin inhibits cancer cell proliferation and induces apoptosis through multiple mechanisms, including blockade of PI3K/AKT, Wnt/β-catenin, and STAT3 signaling, upregulation of pro-apoptotic proteins Bax and caspase-3/9, downregulation of Bcl-2, and inhibition of G6PD to impair cancer cell metabolism. Tumor growth suppression has been demonstrated in hepatocellular carcinoma xenograft mouse models, and synergy with tyrosine kinase inhibitors against drug-resistant cancer lines has been reported in cell studies. However, no human clinical oncology trials have been conducted, so these findings cannot yet be extrapolated to clinical cancer treatment recommendations.

### How does polydatin work in the body to reduce inflammation?

Polydatin reduces inflammation by suppressing the TLR4/NF-κB p65 signaling pathway, which is responsible for triggering pro-inflammatory responses in cells. This mechanism helps lower the production of inflammatory mediators and has been demonstrated in models of LPS-induced neuroinflammation, making it particularly relevant for conditions involving immune activation and tissue damage.

### What is the evidence for polydatin's antioxidant effects in the brain and heart?

Clinical and preclinical research shows that polydatin activates the Keap1/Nrf2 pathway—a master regulator of cellular antioxidant defense—leading to increased expression of protective enzymes like heme oxygenase-1 (HO-1). Studies in ischemia-reperfusion injury and neuroinflammation models demonstrate significant reductions in reactive oxygen species (ROS) and reactive nitrogen species (RNS), supporting its potential for neuroprotection and cardiovascular health.

### What foods contain polydatin, and can I get sufficient amounts from diet alone?

Polydatin is naturally present in Polygonum cuspidatum (Japanese knotweed) and some red wines, but dietary concentrations are typically very low compared to therapeutic supplement doses. Most people cannot obtain clinically relevant amounts of polydatin from food sources alone, which is why supplementation is the primary way to achieve the doses used in research studies.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*